Pfizer spends $14B on Medivation in cancer fight

FILE - In this Monday, Nov. 23, 2015, file photo, a man enters Pfizer's world headquarters, in New York. Pfizer is buying biopharmaceutical company Medivation in a deal valued at about $14 billion. Medivation Inc.’s stock soared more than 19 percent in Monday, Aug. 22, 2016 premarket trading. (AP Photo/Mark Lennihan, File)

Pfizer will pay about $14 billion to buy cancer drug developer Medivation in a cash deal aimed at fortifying its hold in one of the hottest and most lucrative areas of medicine.

The New York drugmaker said Monday that the acquisition will stock its product portfolio with leading treatments for the most common cancers in men and women by adding Medivation's pricey prostate cancer treatment Xtandi to a lineup that already includes the breast cancer drug Ibrance.

Pfizer CEO Ian Read called the acquisition a "rare opportunity" to add an established treatment and a pipeline of drugs under development.

Medivation presents an attractive target as a specialty drugmaker focused on developing medicines for cancer and serious diseases with few treatment options. Earlier this year, it rejected a $9.3 billion offer from the French drugmaker Sanofi.

Pfizer, best known for mass-market drugs such as impotence pill Viagra and cholesterol fighter Lipitor, began pursuing cancer drugs well after most industry leaders. It has been furiously playing catch up, mainly through partnerships with university researchers and other drugmakers.

Last year, Medivation brought in $943 million in revenue, mainly through Xtandi, which it sells in partnership with the Japanese drugmaker Astellas Pharma.

Xtandi has drawn attention from the public interest group Knowledge Economy International, which has protested the $129,000-a year list price for the treatment. The U.S. government covers much of the cost for Xtandi prescriptions filled under federal health programs such as Medicare, Medicaid and the Veterans Administration.

Aside from Xtandi, Pfizer Inc. said Medivation also has a promising pipeline of cancer drugs in late-stage clinical development. That includes the potential breast cancer treatment talazoparib and a potential lymphoma drug. Researchers also are studying Xtandi as a possible treatment for earlier-stage prostate cancers.

Pfizer said Monday that it will pay $81.50 per Medivation share. That's a 21 percent premium to the San Francisco biotech's Friday closing price of $67.19.

The boards of both companies have approved the deal, which is targeted to close in the third or fourth quarter.

The Pfizer-Medivation deal is much smaller than Pfizer's proposed, $160-billion combination with Ireland's Allergan, a plan the drugmakers scrapped after the Treasury Department issued new rules this spring aimed specially at blocking that deal. It was structured as a tax inversion, which means Pfizer's headquarters would move, on paper only, from New York to reduce the drugmaker's U.S. tax bill.

There has been a push from Wall Street for the drugmaker to break itself up into smaller companies so that it can grow faster. While hesitant, Pfizer has promised to decide the issue by the end of this year.

In the meantime, the company has focused on a series of partnerships and deals showing the company can grow as a whole. And company shares have begun to climb after years in the doldrums.

Shares are up 8 percent this year, outpacing all major U.S. trading indexes.

BernsteinResearch analyst Dr. Tim Anderson, who has pushed repeatedly for a breakup, wrote that paying more than $80 per share "for a stock that was trading in the $30s just a few months ago feels pricey" at first glance.

Shares of Medivation Inc. soared nearly 20 percent, or $13.33, to $80.49 early Monday, while Pfizer climbed 22 cents to $35.20.

___

Murphy reported from Indianapolis, and Johnson contributed from Trenton, New Jersey.

Must Read

AP witnesses rescue of migrants off Libya, 4 bodies found

Aug 18, 2016

A Spanish aid group rescued more than 100 migrants Thursday from three separate migrant boats off...

Image of Asia: Protesting killings of civilians in Kashmir

Aug 22, 2016

Image of Asia: Neighbors and relatives of a man killed by a tear gas shell shout anti-India slogans...

Italy, German, French eye beefed up EU defense after attacks

Aug 22, 2016

The leaders of Italy, France and Germany vowed Monday to improve European-wide security efforts in...

How to get ready for your VW payout

Aug 25, 2016

VW's proposed settlement in the wake of its diesel scandal is complicated but owners can get an...

UN condemns 4 North Korean ballistic missile launches

Aug 27, 2016

The UN Security Council is strongly condemning four North Korean ballistic missile launches in July...

People also read these

Speedo USA, 3 other sponsors drop Lochte after Rio incident

Aug 22, 2016

Ryan Lochte loses four major sponsors over a drunken incident during the Rio Olympics that he...

Image of Asia: Developing football skills in Pyongyang

Aug 24, 2016

Image of Asia: Youths play with a ball during a break at Pyongyang International Football School in...

Soldier who killed 5 Dallas officers showed PTSD symptoms

Aug 25, 2016

The Army reservist who killed five Dallas police officers last month showed symptoms of...

Mylan boosts EpiPen patient programs, doesn't budge on price

Aug 25, 2016

Mylan, now in the crosshairs over severe price hikes for its EpiPen, says that it going to expand...

Image of Asia: Speaking to Taiwan's troops at military drill

Aug 25, 2016

Image of Asia: Taiwan's President Tsai Ing-wen delivers a speech at a military exercise in southern...

Weather, 20 December
Houston Weather
+7

High: +11° Low: -2°

Humidity: 83%

Wind: NNE - 7 KPH

Canberra Weather
+27

High: +27° Low: +17°

Humidity: 87%

Wind: W - 20 KPH

Roissy-en-France Weather
+6

High: +6° Low: -5°

Humidity: 87%

Wind: ENE - 7 KPH

Florence Weather
+9

High: +9° Low: +6°

Humidity: 97%

Wind: ENE - 17 KPH

Parga Weather
+7

High: +16° Low: +4°

Humidity: 100%

Wind: SE - 25 KPH